Equities Analysts Issue Forecasts for TVTX Q3 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at HC Wainwright lifted their Q3 2026 earnings estimates for Travere Therapeutics in a research report issued to clients and investors on Wednesday, August 5th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $0.10 per share for the quarter, up from their prior estimate of ($0.10). HC Wainwright currently has a “Buy” rating and a $67.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for Travere Therapeutics’ Q4 2026 earnings at $0.24 EPS, FY2027 earnings at $1.47 EPS, FY2028 earnings at $3.52 EPS, FY2029 earnings at $4.24 EPS and FY2030 earnings at $5.73 EPS.

Several other research firms have also recently commented on TVTX. Canaccord Genuity Group upped their price target on Travere Therapeutics from $62.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Citigroup boosted their price objective on Travere Therapeutics from $70.00 to $85.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price for the company in a research note on Tuesday, April 14th. Wedbush raised their target price on Travere Therapeutics from $61.00 to $75.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Finally, TD Cowen lifted their price target on shares of Travere Therapeutics from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $61.67.

Travere Therapeutics Stock Down 1.1%

TVTX stock opened at $60.21 on Wednesday. Travere Therapeutics has a twelve month low of $17.05 and a twelve month high of $66.24. The company has a market cap of $5.68 billion, a PE ratio of -130.89 and a beta of 1.12. The business’s 50-day simple moving average is $55.54 and its 200 day simple moving average is $41.83. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in TVTX. GAMMA Investing LLC raised its position in shares of Travere Therapeutics by 53.4% during the second quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after acquiring an additional 211 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Travere Therapeutics by 69.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after acquiring an additional 487 shares during the period. Comerica Bank boosted its holdings in Travere Therapeutics by 77.5% in the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after acquiring an additional 492 shares during the last quarter. ProShare Advisors LLC boosted its holdings in Travere Therapeutics by 4.1% in the fourth quarter. ProShare Advisors LLC now owns 19,007 shares of the company’s stock valued at $726,000 after acquiring an additional 756 shares during the last quarter. Finally, Allworth Financial LP acquired a new stake in Travere Therapeutics in the second quarter worth about $47,000.

Insider Buying and Selling

In other Travere Therapeutics news, Director Roy D. Baynes sold 4,500 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $50.00, for a total value of $225,000.00. Following the sale, the director directly owned 41,500 shares in the company, valued at $2,075,000. This represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Timothy Coughlin sold 10,000 shares of the stock in a transaction on Friday, June 12th. The stock was sold at an average price of $50.07, for a total value of $500,700.00. Following the transaction, the director owned 56,250 shares of the company’s stock, valued at $2,816,437.50. This represents a 15.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 4.44% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.